Suppr超能文献

胶质母细胞瘤干细胞中微管蛋白表达降低会减弱微管靶向药物的疗效。

Lower Tubulin Expression in Glioblastoma Stem Cells Attenuates Efficacy of Microtubule-Targeting Agents.

作者信息

Abbassi Ramzi H, Recasens Ariadna, Indurthi Dinesh C, Johns Terrance G, Stringer Brett W, Day Bryan W, Munoz Lenka

机构信息

Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, John Hopkins Drive, Sydney, New South Wales 2006, Australia.

Oncogenic Signalling Laboratory and Brain Cancer Discovery Collaborative, Telethon Kids Institute, Perth Children's Hospital, 15 Hospital Avenue, Nedlands, Western Australia 6009, Australia.

出版信息

ACS Pharmacol Transl Sci. 2019 Jul 30;2(6):402-413. doi: 10.1021/acsptsci.9b00045. eCollection 2019 Dec 13.

Abstract

Sensitivity to microtubule-targeting agents (MTAs) varies among cancers and predicting the response of individual cancer patients to MTAs remains challenging. As microtubules possess vast molecular heterogeneity generated by tubulin isotypes and their post-translational modifications, we questioned whether this heterogeneity can impact MTA sensitivity. We investigated microtubule heterogeneity in 15 glioblastoma cell lines and measured sensitivity of orthogonal MTAs using a per-division growth rate inhibition method that corrects for the confounding effects of variable cell proliferation rates. We found that the tubulin profile is unique for each glioblastoma cell line and that the total α- and β-tubulin levels impact on MTA sensitivity. The baseline levels of α- and β-tubulin were up to 20% lower in cells that were not effectively killed by MTAs. We report that lower α/β-tubulin expression is associated with lack of cell differentiation and increased expression of stemness markers. The dedifferentiated stem-like cells with low α/β-tubulin levels survive MTAs treatment via reversible nonmutational dormancy. Our findings provide novel insights into the relationships between microtubules and MTAs and lay a foundation for better understanding of the sensitivity of cancer cells to MTAs.

摘要

不同癌症对微管靶向药物(MTA)的敏感性存在差异,预测个体癌症患者对MTA的反应仍然具有挑战性。由于微管具有由微管蛋白异构体及其翻译后修饰产生的巨大分子异质性,我们质疑这种异质性是否会影响MTA敏感性。我们研究了15种胶质母细胞瘤细胞系中的微管异质性,并使用校正可变细胞增殖率混杂效应的每分裂生长率抑制方法测量了正交MTA的敏感性。我们发现每个胶质母细胞瘤细胞系的微管蛋白谱都是独特的,并且总α-和β-微管蛋白水平会影响MTA敏感性。在未被MTA有效杀死的细胞中,α-和β-微管蛋白的基线水平低至20%。我们报告说,较低的α/β-微管蛋白表达与细胞分化缺乏和干性标志物表达增加有关。具有低α/β-微管蛋白水平的去分化干细胞样细胞通过可逆的非突变性休眠在MTA治疗中存活。我们的研究结果为微管与MTA之间的关系提供了新的见解,并为更好地理解癌细胞对MTA的敏感性奠定了基础。

相似文献

3
Microtubules in apoptosis induction: are they necessary?凋亡诱导中的微管:它们是必需的吗?
Curr Cancer Drug Targets. 2007 Dec;7(8):713-29. doi: 10.2174/156800907783220480.
4
Microtubule-targeting agents and their impact on cancer treatment.微管靶向药物及其对癌症治疗的影响。
Eur J Cell Biol. 2020 May;99(4):151075. doi: 10.1016/j.ejcb.2020.151075. Epub 2020 May 1.
7
Marine Derived Anticancer Drugs Targeting Microtubule.靶向微管的海洋来源抗癌药物
Recent Pat Anticancer Drug Discov. 2017;12(2):102-127. doi: 10.2174/1574892812666170109141003.
8
Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton.微管靶向药物:劫持细胞骨架的策略。
Trends Cell Biol. 2018 Oct;28(10):776-792. doi: 10.1016/j.tcb.2018.05.001. Epub 2018 Jun 2.

引用本文的文献

本文引用的文献

2
Targeting Cancer Cell Dormancy.靶向肿瘤休眠细胞
Trends Pharmacol Sci. 2019 Feb;40(2):128-141. doi: 10.1016/j.tips.2018.12.004. Epub 2019 Jan 3.
4
Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton.微管靶向药物:劫持细胞骨架的策略。
Trends Cell Biol. 2018 Oct;28(10):776-792. doi: 10.1016/j.tcb.2018.05.001. Epub 2018 Jun 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验